Combined Aspirin–Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease
Open Access
- 22 January 2007
- journal article
- review article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 167 (2) , 117-124
- https://doi.org/10.1001/archinte.167.2.117
Abstract
Combination antithrombotic therapy consisting of low-dose aspirin (≤100 mg/d) and an oral anticoagulant (OAC) is recommended only for patients with a mechanical prosthetic heart valve.1 Despite this recommendation, a considerable number of patients with chronic atrial fibrillation receive combined aspirin-OAC therapy. In 2 recent multinational clinical trials involving patients with chronic atrial fibrillation, 25% of patients were receiving aspirin in addition to OAC therapy.2This publication has 7 references indexed in Scilit:
- Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillationJournal of the American College of Cardiology, 2004
- Combined Anticoagulant–Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation PatientsStroke, 2004
- Antithrombotic Therapy in Valvular Heart Disease—Native and ProstheticChest, 2004
- The optimal intensity of vitamin k antagonists in patients with mechanical heart valvesJournal of the American College of Cardiology, 2003
- Measuring inconsistency in meta-analysesBMJ, 2003
- Effect of Low-Dose Aspirin on the International Normalized Ratio Variability in Patients with Mechanical Heart Valve ProsthesesPathophysiology of Haemostasis and Thrombosis, 2002
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor strokeThe Lancet, 1993